@article{Klimek_L-2020_26822,
title = {Handling of allergen immunotherapy in the COVID-19 pandemic:An ARIA-EAACI statement},
author = {Klimek, L. and Jutel, M. and Akdis, C. and Bousquet, J. and Akdis, M. and Bachert, C. and Agache, I. and Ansotegui, I. and Bedbrook, A. and Bosnic-Anticevich, S. and Canonica, G. and Chivato, T. and Cruz, A. and Czarlewski, W. and Del Giacco, S. and Du, H. and Fonseca, J. and Gao, Y. and Haahtela, T. and Hoffmann‐Sommergruber, K. and Ivancevich, J. and Khaltaev, N. and Knol, E. and Kuna, P. and Larenas-Linnemann, D. and Melén, E. and Mullol, J. and Naclerio, R. and Ohta, K. and Okamoto, Y. and O'Mahony, L. and Onorato, G. and Papadopoulos, N. and Pawankar, R. and Pfaar, O. and Samolinski, B. and Schwarze, J. and Toppila-Salmi, S. and Shamji, M. and Ventura, M. and Yorgancioglu, A. and Matricardi, P. and Zuberbier, T.},
month = {apr},
year = {2020},
abstract = {The current COVID-19 pandemic influences many areas of social life, medical treatments and the way allergy is performed. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on immunological effects on the diseased patient.},
pages = {1546-1554},
volume = {75},
issue = {7},
journal = {Allergy},
publisher = {Wiley},
url = {https://doi.org/10.1111/all.14336},
}
